Clinic
Crown Heights Medical, P.C.
Crown Heights Medical, P.C. was paid $56.63M by Medicaid between Oct 2020 and Nov 2024, across 42 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 58% of everything it billed.
33Billing provider infoCROWN HEIGHTS MEDICAL, P.C.
MONSEY, NY 10952
MONSEY, NY 10952
33aNPI1821210402assigned 05/03/2007
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$56.63M
24GClaims1,729,691
24DCodes billed42
24AFirst – last monthOct 2020 – Nov 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in New York
Rank by total paid#3 of 118
Median peer was paid$372K
This provider vs. median152×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 173 | $5K | |
| 2021 | 217,672 | $6.84M | |
| 2022 | 1,151,392 | $38.97M | |
| 2023 | 353,122 | $10.54M | |
| 2024incomplete | 7,332 | $272K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 58% | 507,989 | 143,419 | $32.86M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 19% | 507,554 | 143,336 | $10.71M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 13% | 524,120 | 149,626 | $7.16M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 40,526 | 35,689 | $2.41M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.3% | 9,806 | 9,625 | $740K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16,294 | 12,172 | $495K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,729 | 5,256 | $426K |
| S9083 | Global fee urgent care centers | <1% | 3,958 | 1,209 | $301K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 6,327 | 6,141 | $298K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 3,439 | 3,189 | $292K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 28,073 | 13,195 | $277K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 9,037 | 8,313 | $216K |
30 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,925 | $120K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 16,979 | $86K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 489 | $53K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,524 | $30K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,483 | $25K |
| 87070 | <1% | 3,598 | $21K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 936 | $18K |
| 87184 | <1% | 3,529 | $17K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 653 | $14K |
| 93000 | <1% | 864 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,134 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 150 | $7K |
| 99000 | <1% | 15,478 | $7K | |
| 81000 | <1% | 1,816 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 40 | $5K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 89 | $4K |
| 92587 | <1% | 172 | $4K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 61 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 169 | $2K |
| 90686 | <1% | 118 | $2K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 27 | $2K |
| 99050 | <1% | 752 | $2K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 15 | $752.25 |
| 81025 | <1% | 167 | $713.28 | |
| H0033 | Oral medication administration, direct observation | <1% | 13 | $318.65 |
| 99195 | <1% | 15 | $156.69 | |
| 99051 | <1% | 13 | $91.91 | |
| 94760 | <1% | 207 | $68.48 | |
| 85018 | <1% | 69 | $66.93 | |
| 2010F | 0% | 354 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKURTZ, SETH (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| QHC Upstate Medical, P.C. | Monsey, NY | $16.63M |
| KJ Medical Practice PC | Monroe, NY | $7.76M |
| Park Avenue Pediatrics, P.C. | Spring Valley, NY | $729K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.